Compassionate Use of Ubamatamab

Sponsor: Regeneron Pharmaceuticals

Expanded Access
Sponsor score: 60

ClinicalTrials ID:NCT07502716

This program addresses Compassionate Use requests for ubamatamab through Individual Patient IND applications. Eligibility criteria are not specified. The intervention involves the administration of ubamatamab, a drug under investigation. This initiative aims to provide access to ubamatamab for patients who may benefit from its use outside of clinical trials.

Patient Parameters

Program Overview

Provide Compassionate Use of Ubamatamab

Description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.

Eligibility Criteria

Eligibility will be determined during the application review process.

Get This Program In Your Inbox

You can sign up and apply your patients for this program.